568 results on '"Alcamí, José"'
Search Results
2. High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells
3. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants
4. Maca (Lepidium meyenii Walp.) inhibits HIV-1 infection through the activity of thiadiazole alkaloids in viral integration
5. Novel HIV-1 RNA biogenesis inhibitors identified by virtual pharmacophore-based screening
6. Immunological and virological findings in a patient with exceptional post-treatment control: a case report
7. HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights
8. Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
9. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
10. The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans
11. Elite controllers long-term non progressors present improved survival and slower disease progression
12. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
13. Overview of SARS-CoV-2 infection in adults living with HIV
14. Exploring the HIV-1 Rev Recognition Element (RRE)–Rev Inhibitory Capacity and Antiretroviral Action of Benfluron Analogs
15. Situación de la investigación sobre el VIH en España
16. Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV
17. HLA-B*57 and IFNL4-Related Polymorphisms Are Associated With Protection Against HIV-1 Disease Progression in Controllers
18. Nucleic acid recognition and antiviral activity of 1,4-substituted terphenyl compounds mimicking all faces of the HIV-1 Rev protein positively-charged α-helix
19. Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination
20. Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
21. Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern
22. Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins
23. Analysis of Non-AIDS-Defining Events in HIV Controllers
24. Transcriptome Sequencing of Peripheral Blood Mononuclear Cells from Elite Controller-Long Term Non Progressors
25. HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study
26. Immunological and virological findings in a patient with exceptional post-treatment control: a case report
27. Genetic Study of SARS-CoV-2 Non Structural Protein 12 in COVID-19 Patients Non Responders to Remdesivir
28. Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV
29. Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster
30. Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers
31. Omic Technologies in HIV: Searching Transcriptional Signatures Involved in Long-Term Non-Progressor and HIV Controller Phenotypes
32. HIV and aging, biological mechanisms, and therapies: What do we know?
33. HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines
34. Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control
35. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells
36. EC50 and CC50 of 39 antiviral drug candidates
37. Gating strategy for the identification of cell subpopulations in the human lung tissue model
38. S4 Fig - Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells
39. Antiviral drug candidates for entry inhibition of SARS-CoV-2
40. Gating strategy for the identification of anti-inflammatory effects of selected compounds
41. Optimization of lung tissue enzymatic digestion visualized by t-distributed Stochastic Neighbor Embedding (tSNE), and representative SPC and ACE2 expression
42. Visual summary of the HLT model
43. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells
44. Análisis de la implantación de un sistema de notificación y registro de eventos adversos en el proceso asistencial de una mutua de accidentes de trabajo
45. Olean-18-ene triterpenoids from Celastraceae species inhibit HIV replication targeting NF-kB and Sp1 dependent transcription
46. Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection
47. Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control
48. Natural killer cells act as an extrinsic barrier for in vivo reprogramming
49. Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients
50. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.